Scott A. Boerner

PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation

Jill K. Slack‐Davis, Scott T. Eblen, Maja Zečević et al. · The Journal of Cell Biology · 2003 · 276 citations · Full text

Life Sciences, Biochemistry, Cell Biology +17

The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.

Charles Erlichman, Scott A. Boerner, Christopher G. Hallgren et al. · PubMed · 2001 · 223 citations

Medicine, Oncology, Pharmacology +17

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

Joseph P. Eder, Geoffrey I. Shapiro, Leonard J. Appleman et al. · Clinical Cancer Research · 2010 · 193 citations · Full text

Medicine, Oncology, Pharmacology +17

A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer

Kimberly A. Chianese‐Bullock, William P. Irvin, Gina R. Petroni et al. · Journal of Immunotherapy · 2008 · 110 citations

Medicine, Immunology, Oncology +17

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Patricia LoRusso, Jing Li, Angelika M. Burger et al. · Clinical Cancer Research · 2016 · 109 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17